Moderna and Merck’s Intismeran Shows Positive Interim Phase 3 Results
Successfully Meets Primary Endpoints in Clinical Analysis
Personalized Immune Education Using Patient-Specific Cancer Cell Traits
Questions Remain About Applicability to

The messenger ribonucleic acid (mRNA) technology, which gained fame as a COVID-19 vaccine platform, has begun to break through the late-stage clinical barriers in cancer treatment as well. Moderna and US-based Merck (MSD) have, for the first time, proven efficacy in a phase 3 clinical trial with a personalized mRNA cancer vaccine that is custom-made for each patient's tumor genetic profile. However, expanding the indications to cancers other than melanoma, and reducing the manufacturing time and costs of patient-specific therapies, remain challenges that must be addressed in the future.

[Why&Next]How Did mRNA Overcome the Barriers of 'Cancer Vaccines'? View original image

According to the pharmaceutical and biotech industry as of August 21, the “Intismeran Autogene (V940),” which was co-developed by Moderna and Merck, met its primary endpoints in an interim analysis of a phase 3 clinical trial involving 1,137 high-risk melanoma patients. The group of patients who received both Intismeran and Keytruda after surgery showed a significant reduction in cancer recurrence and distant metastasis compared to those who received Keytruda alone. This marks the first instance in which an mRNA-based cancer therapy has yielded positive phase 3 clinical results.


On the day of the announcement, Moderna’s share price soared by 177%. The shares of other companies developing mRNA cancer vaccines in a similar fashion, such as BioNTech, also surged. Investment sentiment is heating up as mRNA technology, which has so far been concentrated on infectious disease vaccines post-COVID-19, has now proven efficacy in late-stage clinical trials for cancer treatment as well.


[Why&Next]How Did mRNA Overcome the Barriers of 'Cancer Vaccines'? View original image

The Body Learns Cancer’s Features... A Different Drug For Every Patient


mRNA plays a role in delivering instructions for the cell to produce specific proteins. The COVID-19 vaccines were developed based on the principle of encoding information about a virus’s spike proteins into mRNA, prompting the body’s cells to produce matching proteins. The immune system then recognizes these proteins as markers of foreign invaders and responds rapidly when the actual virus appears. This principle can also be applied to cancer treatment. Instead of a virus, the immune system is trained to recognize traits unique to a patient’s cancer cells. As genetic mutations accumulate in cancer cells, they can produce “neoantigens” that are not present in normal cells.


Intismeran analyzes a patient’s tumor and normal tissue to find mutations unique to the cancer, and then selects the neoantigens most likely to generate an immune response. Information on up to 34 neoantigens is then encoded into mRNA to create a personalized therapy for each patient. When these mRNA-encoded neoantigens are presented to the immune system, T cells learn to recognize and attack cancer cells with the same features.


Intismeran Surpasses Decades of Challenges


The history of therapeutic cancer vaccine development spans decades. Although development was attempted for a variety of cancers, including brain, lung, and kidney cancers, few succeeded in late-stage clinical trials. This is because the antigens expressed by cancer cells vary from case to case, and targeting just one antigen allows cancer cells lacking that antigen to survive. The ability of cancer cells to suppress immune responses, thereby evading T cell attacks, has also been a significant obstacle.


[Why&Next]How Did mRNA Overcome the Barriers of 'Cancer Vaccines'? View original image

Intismeran addresses these challenges from multiple angles. It simultaneously targets up to 34 neoantigens in each patient and is administered after surgical removal of the tumor, when the number of cancer cells in the body is relatively low. In addition, its combination with Keytruda blocks signals that suppress T cell immune responses. The integration of technologies that identify patient-specific targets through genome analysis, mRNA platforms capable of encoding multiple neoantigens, and immune checkpoint inhibitors has made it possible to offer a new type of therapy distinct from past cancer vaccines.


Marco Gerlinger, a professor at the UK’s Barts Cancer Institute, told the UK Science Media Centre (SMC), “This achievement is important because it provides proof-of-concept that personalized cancer vaccines can work. It is also significant in that the approach can be designed for various cancer types.” Leonard Lee, a professor at the University of Oxford, also assessed the results as “the first positive phase 3 for both a patient-personalized neoantigen therapeutic and an mRNA-based cancer treatment.”


Will It Work For Other Cancers? Commercialization Challenges Remain


However, it remains to be seen whether this success can be replicated for other types of cancer. Melanoma is a representative cancer with a high tumor mutation burden (TMB), meaning it has a large number of genetic mutations and thus more neoantigen candidates for the immune system to recognize. By contrast, cancers with fewer mutations, or where epigenetic changes play a major role in cancer development, are more challenging as mRNA vaccines may struggle to identify suitable targets.


The findings released this time are also from an interim analysis of the phase 3 trial. Concrete data on how much the risk of recurrence was reduced, the effects among different patient groups, and overall survival (OS) have yet to be published. Professor Gerlinger commented, “Long-term improvement in survival can only be confirmed by following patients for longer periods.”



The fact that each patient’s therapy must be individually produced is another issue that must be resolved for commercialization. Tumor tissue must be analyzed to find mutations and select neoantigens, and the process of designing and producing mRNA has to be repeated for each patient. Unlike conventional drugs that can be mass produced as identical products, the increasing number of patients means that more diverse therapies need to be manufactured simultaneously. Therefore, analysts point out that the key will be how much time and cost can be reduced in manufacturing.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing